August 4, 2022

BSE Limited **Code: 532321**
1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited **Code: Zyduslife**
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed copy of press releases dated August 4, 2022 titled "**Zydus receives final approval from the USFDA for Ivermectin Cream**" and "**Zydus receives final approval from the USFDA for Empagliflozin Tablets**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2022.08.04 11:25:03 +05'30'

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from the USFDA for Ivermectin Cream

Ahmedabad, India, 04 August, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ivermectin Cream, 1%. USRLD: Soolantra.

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea. The drug will be manufactured at the group's topical manufacturing facility at Ahmedabad, India.

Ivermectin Cream had annual sales of USD 176 million in the United States according to IQVIA data (IQVIA MAT June 2022).

The group now has 319 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

*(*as of 31st March 2022)*

****

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

Zydus receives final approval from the USFDA for Empagliflozin Tablets

Ahmedabad, India, 04 August, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin Tablets USP 10 mg and 25 mg. USRLD: Jardiance.

Empagliflozin is used to lower blood sugar levels in people with type 2 diabetes. Itis also used to reduce the risk of stroke, heart attack, or death in people with type 2 diabetes along with heart and blood vessel disease. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Empagliflozin Tablets had annual sales of USD 9,810 million in the United States according to IQVIA data (IQVIA MAT June 2022).

The group now has 319 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

*(*as of 31st March 2022)*

****

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878